NC762 

NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

B7-H4/VTCN1

NC762 (0.01-100 nM) 与 B7-H4 结合，在 624Mel.B7H4 细胞中 EC₅₀ 为 1.12 nM，在 SKBR3 细胞中 EC₅₀ 为 0.976 nM^[2]。
NC762 (0.1 ng/mL-100 μg/mL) 与人源 293T 细胞中的 B7-H4 结合，但不与小鼠 B7-H4 结合^[2]。
NC762 (0.1 pM-1000 nM) 和 V5.hlgG₁ 相比增强了与 CD16a 的结合^[2]。
NC762 (0.1-100 pM，5 小时) 在与 Jurkat 效应细胞系一起培养的 624Mel.B7H4 和 SKBR3 中表现出 ADCC 活性^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

NC762 (1-30 mg/kg，腹腔注射，每 7 天给药共 4 次) 在皮下接种 1E06 个 624Mel.hB7H4 细胞和 3E05 个人源 PBMC 的 NSG 小鼠中，以剂量依赖性的方式缩小了肿瘤体积^[2]。
NC762 (10 mg/kg，腹腔注射，每 4 天给药共 7 次) 在皮下接种 1E06 个 624Mel.hB7H4 细胞和 1E06 个总 PBMC 或 NK 细胞耗尽的 PBMC 的 NSG 小鼠模型中，显示 NK 细胞有助于抗 B7H4 介导的肿瘤生长减少并延长了小鼠的生存期^[2]。
NC762 (10 mg/kg，腹腔注射，每 7 天给药共 4 次) 在皮下接种了没有 PBMC 或者存在人类 T 细胞的 1E06 624Mel.hB7H4 细胞的 NSG 小鼠模型中，显示出在没有 PBMC 的情况下肿瘤生长受到限制^[2]。
NC762 (10 mg/kg，腹腔注射，每 7 天给药共 4 次) 抑制肿瘤生长的活性与皮下接种 1E06 624Mel.hB7H4 细胞的 NSG 小鼠中 Fc 亲和力较低的 NC762 突变体相似，表明存在一种不依赖 ADCC 的肿瘤生长限制机制^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

79679  [NCBI]

Q7Z7D3

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Myint, Han, et al. "748 A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors." (2022).

  [2]. Kristina Archer, et al. Abstract 3193: Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies. Cancer Res 1 July 2021; 81 (13_Supplement): 3193.